These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 37439934)
21. Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis. Pons-Escoda A; Garcia-Ruiz A; Naval-Baudin P; Grussu F; Fernandez JJS; Simo AC; Sarro NV; Fernandez-Coello A; Bruna J; Cos M; Perez-Lopez R; Majos C Eur Radiol; 2022 Jun; 32(6):3705-3715. PubMed ID: 35103827 [TBL] [Abstract][Full Text] [Related]
22. DSC-PWI presurgical differentiation of grade 4 astrocytoma and glioblastoma in young adults: rCBV percentile analysis across enhancing and non-enhancing regions. Pons-Escoda A; Naval-Baudin P; Viveros M; Flores-Casaperalta S; Martinez-Zalacaín I; Plans G; Vidal N; Cos M; Majos C Neuroradiology; 2024 Aug; 66(8):1267-1277. PubMed ID: 38834877 [TBL] [Abstract][Full Text] [Related]
23. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis. Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843 [TBL] [Abstract][Full Text] [Related]
24. Systematic assessment of multi-echo dynamic susceptibility contrast MRI using a digital reference object. Stokes AM; Semmineh NB; Nespodzany A; Bell LC; Quarles CC Magn Reson Med; 2020 Jan; 83(1):109-123. PubMed ID: 31400035 [TBL] [Abstract][Full Text] [Related]
25. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures. Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773 [TBL] [Abstract][Full Text] [Related]
26. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI. Chawla S; Wang S; Mohan S; Nasrallah M; Verma G; Brem S; O'Rourke DM; Wolf RL; Poptani H; Nabavizadeh SA J Magn Reson Imaging; 2019 Jan; 49(1):184-194. PubMed ID: 29676844 [TBL] [Abstract][Full Text] [Related]
27. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI. Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792 [TBL] [Abstract][Full Text] [Related]
28. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging. She D; Xing Z; Cao D J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801 [TBL] [Abstract][Full Text] [Related]
29. Machine learning based on multi-parametric magnetic resonance imaging to differentiate glioblastoma multiforme from primary cerebral nervous system lymphoma. Nakagawa M; Nakaura T; Namimoto T; Kitajima M; Uetani H; Tateishi M; Oda S; Utsunomiya D; Makino K; Nakamura H; Mukasa A; Hirai T; Yamashita Y Eur J Radiol; 2018 Nov; 108():147-154. PubMed ID: 30396648 [TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient. Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023 [TBL] [Abstract][Full Text] [Related]
31. Usefulness of enhancement-perfusion mismatch in differentiation of CNS lymphomas from other enhancing malignant tumors of the brain. Goyal P; Kumar Y; Gupta N; Malhotra A; Gupta S; Gupta S; Mangla M; Mangla R Quant Imaging Med Surg; 2017 Oct; 7(5):511-519. PubMed ID: 29184763 [TBL] [Abstract][Full Text] [Related]
32. The role of dynamic susceptibility contrast-enhanced perfusion MR imaging in differentiating between infectious and neoplastic focal brain lesions: results from a cohort of 100 consecutive patients. Floriano VH; Torres US; Spotti AR; Ferraz-Filho JR; Tognola WA PLoS One; 2013; 8(12):e81509. PubMed ID: 24324699 [TBL] [Abstract][Full Text] [Related]
33. Differentiation of primary central nervous system lymphoma from high-grade glioma and brain metastasis using arterial spin labeling and dynamic contrast-enhanced magnetic resonance imaging. Xi YB; Kang XW; Wang N; Liu TT; Zhu YQ; Cheng G; Wang K; Li C; Guo F; Yin H Eur J Radiol; 2019 Mar; 112():59-64. PubMed ID: 30777220 [TBL] [Abstract][Full Text] [Related]
34. Differentiation of glioblastoma and primary central nervous system lymphomas using multiparametric diffusion and perfusion magnetic resonance imaging. Hung ND; Anh NN; Minh ND; Huyen DK; Duc NM Biomed Rep; 2023 Nov; 19(5):82. PubMed ID: 37881606 [TBL] [Abstract][Full Text] [Related]
35. Perfusion measurement in brain gliomas using velocity-selective arterial spin labeling: comparison with pseudo-continuous arterial spin labeling and dynamic susceptibility contrast MRI. Qu Y; Kong D; Wen H; Ou X; Rui Q; Wang X; Lin DD; Qin Q; Wen Z Eur Radiol; 2022 May; 32(5):2976-2987. PubMed ID: 35066634 [TBL] [Abstract][Full Text] [Related]
36. Three-dimensional arterial spin labeling imaging and dynamic susceptibility contrast perfusion-weighted imaging value in diagnosing glioma grade prior to surgery. Ma H; Wang Z; Xu K; Shao Z; Yang C; Xu P; Liu X; Hu C; Lu X; Rong Y Exp Ther Med; 2017 Jun; 13(6):2691-2698. PubMed ID: 28587332 [TBL] [Abstract][Full Text] [Related]
37. Diffuse Large B-Cell Epstein-Barr Virus-Positive Primary CNS Lymphoma in Non-AIDS Patients: High Diagnostic Accuracy of DSC Perfusion Metrics. Pons-Escoda A; García-Ruíz A; Naval-Baudin P; Grussu F; Viveros M; Vidal N; Bruna J; Plans G; Cos M; Perez-Lopez R; Majós C AJNR Am J Neuroradiol; 2022 Nov; 43(11):1567-1574. PubMed ID: 36202547 [TBL] [Abstract][Full Text] [Related]
38. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study. Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic examination performance by using microvascular leakage, cerebral blood volume, and blood flow derived from 3-T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in the differentiation of glioblastoma multiforme and brain metastasis. Server A; Orheim TE; Graff BA; Josefsen R; Kumar T; Nakstad PH Neuroradiology; 2011 May; 53(5):319-30. PubMed ID: 20625709 [TBL] [Abstract][Full Text] [Related]
40. Multiparametric Framework Magnetic Resonance Imaging Assessment of Subtypes of Intracranial Germ Cell Tumors Using Susceptibility Weighted Imaging, Diffusion-Weighted Imaging, and Dynamic Susceptibility-Contrast Perfusion-Weighted Imaging Combined With Conventional Magnetic Resonance Imaging. Li Y; Wang P; Zhang J; Li J; Chen L; Qiu X J Magn Reson Imaging; 2022 Oct; 56(4):1232-1242. PubMed ID: 35278008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]